Activin receptor antagonists for cancer-related anemia and bone disease.

摘要: Introduction: Antagonists of activin receptor signaling may be beneficial for cancer-related anemia and bone disease caused by malignancies such as multiple myeloma solid tumors. Areas covered: We review evidence dysregulated pathways in anemia, myeloma-associated osteolysis, metastatic disease, well potential involvement carcinogenesis. then properties antagonists clinical development. Expert opinion: Sotatercept is a novel fusion protein that functions soluble trap to sequester ligands type IIA (ActRIIA). Preclinically, the murine version sotatercept increased red blood cells (RBC) model chemotherapy-induced inhibited tumor growth metastasis, exerted anabolic effects on diverse models myeloma. Clinically, increases RBC markedly healthy volunteers patients with With rapid onset action differing fr...